Back to top
more

Assertio (ASRT)

(Delayed Data from NSDQ)

$1.54 USD

1.54
1,655,415

-0.12 (-7.23%)

Updated Jul 15, 2024 04:00 PM ET

After-Market: $1.55 +0.01 (0.65%) 5:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (157 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Assertio (ASRT) Q3 Earnings and Revenues Top Estimates

Assertio (ASRT) delivered earnings and revenue surprises of 100.00% and 6.34%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Assertio (ASRT) Q3 Earnings Expected to Decline

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Assertio (ASRT) Reports Q2 Loss, Misses Revenue Estimates

Assertio (ASRT) delivered earnings and revenue surprises of -100.00% and -18.62%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Assertio (ASRT) Beats Q1 Earnings and Revenue Estimates

Assertio (ASRT) delivered earnings and revenue surprises of 225.00% and 85.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

All You Need to Know About Assertio (ASRT) Rating Upgrade to Buy

Assertio (ASRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PDL BioPharma (PDLI) Misses on Q4 Earnings, To Dissolve by Year-End

PDL BioPharma's (PDLI) earnings lag estimates in the fourth quarter. The company announces plan to complete liquidation by the end of 2020.

Assertio (ASRT) Reports Q4 Loss, Tops Revenue Estimates

Assertio (ASRT) delivered earnings and revenue surprises of -200.00% and 17.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Assertio (ASRT) to Report Q4 Earnings: What's in Store?

During Q4 earnings call, Assertio (ASRT) is likely to provide an update on its recently implemented cost-saving initiatives and the sales performance of its marketed drugs.

Assertio (ASRT) Gains But Lags Market: What You Should Know

Assertio (ASRT) closed the most recent trading day at $1.05, moving +0.48% from the previous trading session.

Assertio (ASRT) Dips More Than Broader Markets: What You Should Know

Assertio (ASRT) closed the most recent trading day at $1.11, moving -0.89% from the previous trading session.

Is ASSERTIO THERAPEUTICS, INC (ASRT) Outperforming Other Medical Stocks This Year?

Is (ASRT) Outperforming Other Medical Stocks This Year?

Assertio (ASRT) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Assertio (ASRT) closed at $1.14, marking a -1.72% move from the previous day.

ASRT or PCRX: Which Is the Better Value Stock Right Now?

ASRT vs. PCRX: Which Stock Is the Better Value Option?

Assertio (ASRT) Stock Sinks As Market Gains: What You Should Know

Assertio (ASRT) closed the most recent trading day at $1.07, moving -0.93% from the previous trading session.

Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up

Tyme's (TYME) shares rise as the company inks deal with Eagle Pharmaceuticals to co-promote its investigational cancer metabolism-based therapy, oral SM-88, in the United States.

Intrexon's Blood Cancer Drug Gets Orphan Drug Status From FDA

The FDA grants orphan drug designation to PRGN-3006, a rare cancer candidate in Precigen's portfolio, which is a subsidiary of Intrexon (XON).

Catalyst Gives Preliminary Firdapse Estimates & Other Updates

Catalyst (CPRX) provides preliminary estimates for Firdapse and other corporate updates for 2019.

ASRT vs. PCRX: Which Stock Is the Better Value Option?

ASRT vs. PCRX: Which Stock Is the Better Value Option?

Assertio (ASRT) Upgraded to Strong Buy: What Does It Mean for the Stock?

Assertio (ASRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Assertio to Divest Shingles Pain Drug to Alvogen for $127.5M

Assertio (ASRT) inks a deal to sell Gralise to Alvogen for a total value of $127.5 million.

ASRT vs. PCRX: Which Stock Should Value Investors Buy Now?

ASRT vs. PCRX: Which Stock Is the Better Value Option?

PDL BioPharma (PDLI) Q3 Earnings Beat, LENSAR Drives Sales

PDL BioPharma (PDLI) impresses investors with third-quarter earnings beat. LENSAR laser system bumps up sales as well. However, revenues fall year over year.